Skip to main content
logo
Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
7,000.00
+510.00 (7.86%)
At close: Jan 16, 2026

Revenue by Product

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
Immuno-cancer Drugs - Product
13.36B
Log In
Log In
Log In
Log In
Upgrade
Immuno-cancer Drugs - Product Growth
115.01%
Log In
Log In
Log In
Log In
Upgrade
Service
7.29B
Log In
Log In
Log In
Log In
Upgrade
Service Growth
-7.26%
Log In
Log In
Log In
Log In
Upgrade
Usage Fee
7.10B
Log In
Log In
Log In
Log In
Upgrade
Usage Fee Growth
3251.04%
Log In
Log In
Log In
Log In
Upgrade
Immuno-cancer Drugs - Merchandise
800.00K
Log In
Log In
Log In
Log In
Upgrade
Immuno-cancer Drugs - Merchandise Growth
-94.84%
Log In
Log In
Log In
Log In
Upgrade
Biological Products
-
Log In
Log In
Log In
Log In
Upgrade
Biological Products Growth
-
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202016 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2016 - 2019
North America
9.60B
Log In
Log In
Log In
Log In
Upgrade
Europe
7.37B
Log In
Log In
Log In
Log In
Upgrade
South Korea
6.30B
Log In
Log In
Log In
Log In
Upgrade
South Korea Growth
-55.92%
Log In
Log In
Log In
Log In
Upgrade
Asia
4.43B
Log In
Log In
Log In
Log In
Upgrade
South America
29.46M
Log In
Log In
Log In
Log In
Upgrade
Oceania
10.97M
Log In
Log In
Log In
Log In
Upgrade